Advisors Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19M Buy
87,244
+6,872
+9% +$1.52M 0.32% 52
2025
Q4
$18.4M Buy
80,372
+8,286
+11% +$1.89M 0.31% 51
2025
Q3
$16.7M Sell
72,086
-2,005
-3% -$408K 0.28% 56
2025
Q2
$13.8M Sell
74,091
-2,840
-4% -$528K 0.25% 70
2025
Q1
$16.1M Sell
76,931
-22,373
-23% -$4.35M 0.3% 51
2024
Q4
$17.6M Sell
99,304
-40,794
-29% -$7.5M 0.33% 50
2024
Q3
$27.7M Sell
140,098
-39,044
-22% -$7.29M 0.51% 28
2024
Q2
$30.7M Sell
179,142
-38,077
-18% -$6.31M 0.6% 21
2024
Q1
$39.6M Sell
217,219
-36,274
-14% -$6.25M 0.76% 13
2023
Q4
$39.3M Sell
253,493
-25,482
-9% -$3.72M 0.8% 12
2023
Q3
$41.6M Sell
278,975
-7,464
-3% -$1.1M 0.9% 13
2023
Q2
$38.6M Sell
286,439
-11,799
-4% -$1.73M 0.79% 15
2023
Q1
$47.5M Buy
298,238
+4,561
+2% +$697K 0.97% 10
2022
Q4
$47.5M Sell
293,677
-4,119
-1% -$632K 0.98% 10
2022
Q3
$40M Sell
297,796
-2,113
-0.7% -$303K 0.84% 12
2022
Q2
$45.9M Sell
299,909
-13,366
-4% -$2.04M 0.87% 14
2022
Q1
$50.8M Sell
313,275
-8,384
-3% -$1.22M 0.78% 12
2021
Q4
$43.6M Buy
321,659
+11,090
+4% +$1.31M 0.62% 23
2021
Q3
$33.5M Buy
310,569
+22,764
+8% +$2.6M 0.51% 29
2021
Q2
$32.4M Buy
287,805
+21,794
+8% +$2.45M 0.48% 29
2021
Q1
$28.8M Buy
266,011
+30,762
+13% +$3.29M 0.45% 32
2020
Q4
$25.2M Buy
235,249
+17,268
+8% +$1.66M 0.42% 38
2020
Q3
$19.1M Sell
217,981
-5,191
-2% -$489K 0.35% 46
2020
Q2
$21.9M Sell
223,172
-7,921
-3% -$697K 0.43% 35
2020
Q1
$17.6M Sell
231,093
-33,166
-13% -$2.82M 0.42% 43
2019
Q4
$23.4M Sell
264,259
-34,076
-11% -$2.83M 0.41% 39
2019
Q3
$22.6M Buy
298,335
+10,912
+4% +$748K 0.42% 38
2019
Q2
$20.9M Buy
287,423
+16,940
+6% +$1.33M 0.38% 52
2019
Q1
$21.8M Buy
270,483
+16,991
+7% +$1.39M 0.39% 47
2018
Q4
$22.8M Buy
253,492
+498
+0.2% +$43.8K 0.46% 32
2018
Q3
$23.9M Sell
252,994
-21,389
-8% -$2.03M 0.39% 43
2018
Q2
$25.4M Sell
274,383
-170,102
-38% -$16.6M 0.43% 34
2018
Q1
$51.3M Sell
444,485
-12,242
-3% -$1.34M 0.86% 9
2017
Q4
$44.2M Sell
456,727
-72,265
-14% -$6.81M 0.73% 9
2017
Q3
$47M Sell
528,992
-56,881
-10% -$4.33M 0.79% 9
2017
Q2
$42.5M Sell
585,873
-26,891
-4% -$1.81M 0.71% 10
2017
Q1
$39.9M Sell
612,764
-13,004
-2% -$818K 0.67% 10
2016
Q4
$39.2M Buy
625,768
+1,524
+0.2% +$93K 0.65% 8
2016
Q3
$39.4M Buy
624,244
+85,278
+16% +$5.52M 0.65% 8
2016
Q2
$33.4M Sell
538,966
-31,524
-6% -$1.92M 0.54% 12
2016
Q1
$32.6M Buy
570,490
+87,868
+18% +$4.9M 0.54% 14
2015
Q4
$28.6M Sell
482,622
-42,057
-8% -$2.42M 0.45% 28
2015
Q3
$28.5M Buy
524,679
+55,494
+12% +$3.61M 0.46% 27
2015
Q2
$31.5M Sell
469,185
-43,874
-9% -$2.86M 0.43% 40
2015
Q1
$30M Buy
513,059
+85,500
+20% +$5.17M 0.4% 56
2014
Q4
$28M Buy
427,559
+63,534
+17% +$4.01M 0.38% 63
2014
Q3
$21M Buy
364,025
+128,158
+54% +$7.12M 0.29% 94
2014
Q2
$13.3M Buy
235,867
+100,110
+74% +$5.25M 0.18% 153
2014
Q1
$6.98M Buy
135,757
+79,515
+141% +$4.02M 0.11% 243
2013
Q4
$2.97M Sell
56,242
-6,323
-10% -$311K 0.05% 427
2013
Q3
$2.8M Sell
62,565
-13,370
-18% -$593K 0.05% 415
2013
Q2
$3.14M Buy
+75,935
New +$3.32M 0.06% 374

Other funds holding ABBV

Advisors Asset Management's ABBV Position: Q1 2026 in Review

Advisors Asset Management increased its AbbVie (ABBV) stake by 8.6% in Q1 2026, buying an estimated $1.52M and bringing the position to 87,244 shares worth $19M. The position accounts for 0.32% of the portfolio, ranked #52.

Advisors Asset Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $51.3M in Q1 2018. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Advisors Asset Management held 87,244 shares of AbbVie worth $19M as of Q1 2026.
  • Advisors Asset Management bought 6,872 AbbVie shares in Q1 2026, an estimated $1.52M.
  • AbbVie made up 0.32% of Advisors Asset Management's portfolio in Q1 2026, its #52 holding.
  • Advisors Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Advisors Asset Management's AbbVie position peaked at $51.3M in Q1 2018.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.